Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281983 | 0.85 | L3MBTL1 (0.48) | HRH3TEAD1TEAD3MEN1KMT2A | |
| SCHEMBL4286026 | 0.85 | HPGD (0.49) | KMT2A | |
| SCHEMBL4292379 | 0.83 | KDM1A (0.43) | OPRK1 | |
| SCHEMBL4281735 | 0.83 | HCRTR1 (0.38) | HRH3S1PR5OPRK1S1PR1 | |
| SCHEMBL3494366 | 0.83 | TEAD1 (0.50) | TEAD1TEAD3MEN1KMT2A | |
| SCHEMBL4294542 | 0.83 | KDM4E (0.49) | HRH3 | |
| SCHEMBL4281940 | 0.82 | KCNA5 (0.46) | HRH3MEN1KMT2A | |
| SCHEMBL4286428 | 0.82 | HCRTR1 (0.47) | — | |
| SCHEMBL4287459 | 0.82 | KMT2A (0.49) | HRH3MEN1KMT2A | |
| SCHEMBL4295216 | 0.82 | KMT2A (0.49) | HRH3TEAD1TEAD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HRH3 1248/4885LSS 656/4885TEAD1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.